secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2023-05-01T23:59:59+00:00
Accession:  0000950170-23-016300
Event type: debt
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen enters $75M senior secured term loan with Morgan Stanley Tactical Value; up to $150M total
--------------------------------------------------------------------------------

- Initial $75M term loan funded by May 8, 2023; additional $37.5M milestone-based loan and $37.5M discretionary loan available.
- Interest rate 14.0% per annum payable monthly; maturity May 8, 2026; no amortization payments.
- Minimum $30M unrestricted cash and cash equivalents covenant tested monthly.
- Loans secured by substantially all assets; guarantees from subsidiaries excluding Chinese subsidiary.
- Prepayment requires make-whole amount including remaining scheduled interest to maturity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017023016300/0000950170-23-016300-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017023016300/fgen-20230429.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-016300

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer